FORMYCON AG news, videos and press releases
For more news please use our advanced search feature.
FORMYCON AG - More news...
FORMYCON AG - More news...
- EQS-News: MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
- EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
- EQS-News: Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
- EQS-News: Formycon hosts conference call on the results of the first quarter 2024
- EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
- EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
- EQS-News: Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
- EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
- EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
- EQS-News: Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
- EQS-News: FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
- EQS-News: Gedeon Richter becomes strategic investor of Formycon via equity investment
- EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
- EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
- EQS-News: Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
- EQS-News: Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
- EQS-News: Health Canada approves FYB201/Ranopto® (Ranibizumab), a biosimilar to Lucentis®
- EQS-News: Formycon announces participation in international Investor Conferences in Q1/2024
- EQS-News: Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration
- EQS-News: Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
- EQS-News: Formycon publishes nine-month results for 2023
- EQS-News: Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
- EQS-News: Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
- EQS-News: Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
- EQS-News: Formycon reports successful first half of 2023
- EQS-News: Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
- EQS-News: Formycon hosts conference call on financial and earnings position for H1 2023
- EQS-News: Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar
- EQS-News: Formycon reports on the regular Annual General Meeting
- EQS-News: Formycon announces submission of the biologics license application (BLA) for FYB203, an aflibercept biosimilar candidate to the U.S. Food and Drug Administration (FDA)
